“Clinical Outcomes in Early Breast Cancer Patients on Adjuvant Tamoxifen: Impact of CYP2D6 phenotype and Observed Endoxifen concentrations (LHSC Experience)

Dr. Veera Panuganty, MD.FRCPC.
Medical Oncology Fellow,
London Health Science Centre

Objectives:

- Review genetic variations of CYP2D6 and impact on Tamoxifen metabolism
- Observations from previous studies of Endoxifen and CYP2D6 phenotypes
- Review current research and results of Endoxifen levels and impact on breast cancer outcomes for LHSC patients

THANK YOU TO OUR SPONSORS: